ARTICLE | Deals
Brii Bio, Tsinghua, Third People’s Hospital to develop COVID-19 patient-derived neutralizing antibodies
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 31, 2020 7:49 PM UTC
Updated on Apr 1, 2020 at 2:09 AM UTC
Taking advantage of access to hospitals that have treated some of the earliest COVID-19 patients, Brii Bio has partnered with Tsinghua University and Third People’s Hospital of Shenzhen to discover and develop COVID-19 mAbs derived from patients who have recovered.
The partners plan to begin clinical trials in 3Q20, about six months after picking a lead mAb...
BCIQ Target Profiles